Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial

What Was Tested

Researchers studied Tirzepatide and Semaglutide in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m2 and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m2 with ≥1 ORHD.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Outcomes were assessed from baseline to Week 72, including percent change in body weight, proportions achieving weight-loss thresholds, changes in waist circumference, BMI, cardiometabolic factors, and adverse events.

Between-group comparisons used analysis of covariance.

Changes over time were assessed with a mixed model for repeated measures.

What Was Measured

The subject headings attached to it are Body Mass Index, Japan, Obesity, Semaglutide, Tirzepatide, Weight Loss and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords Japan Society for the Study of Obesity and obesity management.

What This Means in Plain Language

The paper is a randomized study of Tirzepatide and Semaglutide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Current medical research and opinion), a journal based in England.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.